Toshiba Corp Chairman Osamu Nagayama and another board member failed to get shareholder approval for their reappointments, as nine of the other candidates were approved.
Nagayama was under pressure to resign after an independent investigation revealed that Toshiba officials colluded with the Japanese government to control foreign investors’ influence.
Major shareholders and investment fund Effissimo alleged that Toshiba didn't fairly carry out Effissimo's nomination of dissident directors.
They demanded Nagayama's ouster as the latter has the most responsibility in nominating candidates and on the board's behavior.
Besides Effissimo, which owns a 10 percent stake in Toshiba, other foreign investors include Harvard University’s endowment fund and 3D Investment Partners.
Nagayama had vowed to restore transparency, get to the bottom of what happened, and prevent a recurrence.
In an open letter to shareholders, Nagayama sought backing for his reappointment, pledging to be an agent of positive change rather than as a protector of the status quo.


Instagram Outage Disrupts Thousands of U.S. Users
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Washington Post Publisher Will Lewis Steps Down After Layoffs
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



